Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company’s clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Metrics to compare | 6A3Ay | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship6A3AyPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −5.6x | −0.5x | |
PEG Ratio | 0.00 | −0.01 | 0.00 | |
Price/Book | 0.0x | 3.9x | 2.6x | |
Price / LTM Sales | 0.0x | 9.5x | 3.2x | |
Upside (Analyst Target) | 0.0% | 163.9% | 40.5% | |
Fair Value Upside | Unlock | 13.1% | 4.4% | Unlock |